| Literature DB >> 29435113 |
Miguel Angel Merlos Rodrigo1,2, Simona Dostalova1,2, Hana Buchtelova1,2, Vladislav Strmiska1,2, Petr Michalek1,2, Sona Krizkova1,2, Ales Vicha3, Pavla Jencova3, Tomas Eckschlager3, Marie Stiborova4, Zbynek Heger1,2, Vojtech Adam1,2.
Abstract
Human metallothionein-3 (hMT-3), also known as growth inhibitory factor, is predominantly expressed in the central nervous system. hMT-3 is presumed to participate in the processes of heavy metal detoxification, regulation of metabolism and protection against oxidative damage of free radicals in the central nervous system; thus, it could play important neuromodulatory and neuroprotective roles. However, the primary functions of hMT-3 and the mechanism underlying its multiple functions in neuroblastoma have not been elucidated so far. First, we confirmed relatively high expression of hMT-3 encoding mRNA in biopsies (n = 23) from high-risk neuroblastoma subjects. Therefore, we focused on investigation of the impact of hMT-3 up-regulation in N-Myc amplifying neuroblastoma cells. The differentially up-regulated genes involved in biological pathways related to cellular senescence and cell cycle were identified using electrochemical microarray with consequent bioinformatic processing. Further, as experimental verification of microarray data, the cytotoxicity of the cisplatin (CDDP) was examined in hMT-3 and mock cells by MTT and clonogenic assays. Overall, our data strongly suggest that up-regulation of hMT-3 positively correlates with the genes involved in oncogene-induced senescence (CDKN2B and ANAPC5) or apoptosis (CASP4). Moreover, we identified a significant increase in chemoresistance to cisplatin (CDDP) due to hMT-3 up-regulation (24IC50: 7.5 vs. 19.8 μg/ml), indicating its multipurpose biological significance.Entities:
Keywords: apoptosis; chemoresistance; cisplatin; metallothionein; oncogene-induced senescence
Year: 2017 PMID: 29435113 PMCID: PMC5796984 DOI: 10.18632/oncotarget.23333
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Comparison of WT, mock and hMT-3 neuroblastoma (SiMa) cells
The cells were transfected with either pcDNA3.1-GFP-TOPO (mock transfection) or pcDNA3.1-GFP-hMT3-TOPO (hMT-3). Transfection efficiency and cells viability was estimated by (A) fluorescence cell counting, (B) ambient and (C) fluorescence microscopy. For comparison, non-transfected - wild-type (WT) cells are included. The length of scale bar is 30 μm. (D) qRT-PCR showing changes in mRNA encoding hMT-3. Data were analyzed by comparative CT method and presented as relative fold gene expression (2−ΔΔCT). (E) Representative immunoblots analyses of whole-cell lysates evaluated for hMT-3 expression. GAPDH served as loading control. Data with asterisk (*) indicate statistical significance (p < 0.05).
Figure 2Comparative bioinformatical processing of microarray data
(A) Representative microarray heatmaps showing gene expressions in SiMa cells (one spot per one gene). Gray scale intensity represents the rate of individual mRNA expression. (B) hMT-3 induced over-expression of genes was identified to affect the regulation of cellular senescence pathway (data were analyzed by Reactome, http://www.reactome.org/). (C) Schematic drawing of oncogene-induced senescence pathway. Black framings indicate genes identified as up-regulated after hMT-3 transfection. (D) Representative micrographs of wound-healing assay showing slower migration of hMT-3 cells. Micrographs demonstrate the artificial wounds at the experimental start-point (0 h) and the migration of the cells after 48 h incubation. The length of scale bar is 100 μm, n.d. not detected. (E) Quantitation of relative free areas. The values are expressed as the mean of six independent replicates (n = 6). Data with asterisks (*) indicate statistical significance (p < 0.05).
List of genes up- or down-regulated after transfection with hMT-3 or in mock culture
| hMT-3 | ||||
|---|---|---|---|---|
| Up-regulation | ||||
| Gene | Symbol | NCBI database | Fold ratio | SD ( |
| Chondroitin sulfate proteoglycan 2 | NM_004385 | 2.947 | 3.451 | |
| Anaphase promoting complex subunit 5 | NM_016237 | 2.670 | 0.201 | |
| Protein inhibitor of activated STAT, 2 | NM_173206 | 2.089 | 0.537 | |
| Bone morphogenetic protein 1 | NM_001199 | 1.872 | 0.438 | |
| Asp (abnormal spindle)-like, microcephaly associated | NM_018136 | 1.804 | 0.145 | |
| L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain | NM_005327 | 1.672 | 0.201 | |
| Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) | NM_004936 | 1.653 | 0.064 | |
| Glutathione S-transferase M3 | NM_000849 | 1.646 | 0.220 | |
| Centromere protein A, 17kDa | NM_001809 | 1.605 | 0.288 | |
| Caspase 4, apoptosis-related cysteine peptidase | NM_001225 | 1.586 | 0.045 | |
| Hypothetical protein FLJ12443 | NM_024830 | 1.582 | 0.229 | |
| Small nuclear ribonucleoprotein polypeptides B and B1 | NM_003091 | 1.578 | 0.426 | |
| Plasminogen activator, tissue | NM_033011 | 1.544 | 0.004 | |
| DnaJ (Hsp40) homolog, subfamily B, member 6 | NM_058246 | 1.542 | 0.137 | |
| DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 | NM_004728 | 1.540 | 0.147 | |
| Pre-B-cell colony enhancing factor 1 | NM_005746 | 1.538 | 0.075 | |
| Lactate dehydrogenase B | NM_002300 | 1.524 | 0.497 | |
| Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B | NM_001005914 | 1.523 | 0.026 | |
| Metallothionein 3 | NM_005946 | 1.520 | 0.018 | |
| Palmitoyl-protein thioesterase 1 (ceroid-lipofuscinosis, neuronal 1, infantile) | NM_000310 | 1.504 | 0.016 | |
| Histone deacetylase 2 | NM_001527 | 0.470 | 0.315 | |
| X-ray repair complementing defective repair 3 | NM_005432 | 0.458 | 0.162 | |
| CD47 antigen (Rh-related antigen, integrin-associated signal transducer) | NM_001025079 | 0.114 | 0.0109 | |
The list of processes and/or pathways involved in gene regulation in SiMa cells (hMT-3 vs. mock) using gene ontology (GO) annotations and KEGG 10 software
| hMT-3 | |||
|---|---|---|---|
| Up-regulation | |||
| pathway ID | pathway description | observed gene count | false discovery rate |
| GO.0007094 | mitotic spindle assembly checkpoint | 5 | 1.07E-06 |
| GO.0070979 | protein K11-linked ubiquitination | 5 | 1.07E-06 |
| GO.0007093 | mitotic cell cycle checkpoint | 6 | 2.32E-05 |
| GO.0009896 | positive regulation of catabolic process | 8 | 2.35E-05 |
| GO.0031145 | anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process | 5 | 2.35E-05 |
| GO.0045861 | negative regulation of proteolysis | 7 | 4.65E-05 |
| GO.1903047 | mitotic cell cycle process | 8 | 0.0003 |
| GO.0000278 | mitotic cell cycle | 8 | 0.0006 |
| GO:0007155 | ECM-receptor interaction | 1 | 0.0139 |
| GO:0043044 | Notch signaling pathway | 1 | 0.0012 |
Figure 3Investigation of hMT-3 up-regulation on cytotoxicity of CDDP
(A) MTT survival curves of mock and hMT-3 cells exposed to CDDP (1.2–20.0 μg/ml) for 24 h. Inserted are 24IC50 values for both tested cell lines. (B) Percentage of survival after application of CDDP determined by clonogenic assay. Data with asterisk (*) indicate significant differences (p < 0.05). (C) Detailed representative micrographs of clonogenic assay plates showing significant differences between mock and hMT-3 cells survival and also clonogenicity. The length of scale bar is 200 μm. The cells were stained with 0.1% crystal violet. (D) Estimation of apoptotic markers in mock and hMT-3 cultures after CDDP treatment. β-actin served as loading control. (E) Living cell microscopy of CDDP-induced ROS (CellROX, red). Nuclei were counterstained with Hoechst 33258. The length of scale bar is 20 μm.